Daniel Andrés Colón Ríos
MD-PhD StudentAbout
Research
Publications
2026
12P Pan-tumor exDNA-targeting antibody platform enabling nuclear delivery for protein degradation
Ianniello Z, Quijano E, Colón-Ríos D, Rackear M, Glazer P. 12P Pan-tumor exDNA-targeting antibody platform enabling nuclear delivery for protein degradation. ESMO Open 2026, 11: 106115. DOI: 10.1016/j.esmoop.2026.106115.Peer-Reviewed Original Research
2025
Correction: Harnessing ExDNA for precision Exatecan delivery in cancer: a novel antibody-drug conjugate approach
Ianniello Z, Lu H, Quijano E, Colón-Ríos D, Rackear M, Bommireddy V, Ludwig D, Shen Z, Glazer P. Correction: Harnessing ExDNA for precision Exatecan delivery in cancer: a novel antibody-drug conjugate approach. Molecular Cancer 2025, 24: 304. PMID: 41339893, PMCID: PMC12673787, DOI: 10.1186/s12943-025-02539-9.Commentaries, Editorials and LettersHarnessing exDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach
Ianniello Z, Lu H, Quijano E, Colón-Ríos D, Rackear M, Bommireddy V, Ludwig D, Shen Z, Glazer P. Harnessing exDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach. Molecular Cancer 2025, 24: 253. PMID: 41077566, PMCID: PMC12516839, DOI: 10.1186/s12943-025-02462-z.Peer-Reviewed Original Researchtriple-negative breast cancerantibody-drug conjugatesanti-tumor activityblood-brain barriercancer cell linessafety profiletumor selectivitytherapeutic efficacyxenograft modelxenograft models of triple-negative breast cancermodels of triple-negative breast cancerdose-escalation studyprolonged median survivalbone marrow toxicitybystander killing effecttumor-selective targetingnuclear drug deliveryantibody-drug conjugate approachtumor-bearing micetumor growth inhibitioncell linesDNA damage responselong-term treatmentkidney function testsanalysis of hematological parametersPARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7
Colón-Ríos D, Dow J, Krysztofiak A, Liu Y, Rogers F, Glazer P. PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. NAR Cancer 2025, 7: zcaf047. PMID: 41357766, PMCID: PMC12675010, DOI: 10.1093/narcan/zcaf047.Peer-Reviewed Original ResearchThis study investigates how IDH1-mutant cancers develop resistance to PARP inhibitors through loss of end protection factors, 53BP1 and REV7, and shows that the drug cediranib can overcome this resistance, highlighting potential therapeutic strategies for improving cancer treatment outcomes.
2024
Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition
Rackear M, Quijano E, Ianniello Z, Colón-Ríos D, Krysztofiak A, Abdullah R, Liu Y, Rogers F, Ludwig D, Dwivedi R, Bleichert F, Glazer P. Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition. Oncotarget 2024, 15: 699-713. PMID: 39352803, PMCID: PMC11444335, DOI: 10.18632/oncotarget.28651.Peer-Reviewed Original ResearchConceptstumor targetingmonoclonal antibody therapytumor-specific targetingcell uptakenucleic acid bindingcell surface antigensantibody therapyhuman variantsclinical successcell-penetrating antibodiesacid bindingsystemic administrationsurface antigenstumorRAD51 inhibitionantibody platformmechanism of cell penetrationbind RAD51antibodiesfull-lengthspecific targetscell penetrationdisease targetscellsautoantibodies
2021
Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair
Dow J, Krysztofiak A, Liu Y, Colon-Rios DA, Rogers FA, Glazer PM. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. Molecular Cancer Research 2021, 19: 2057-2067. PMID: 34535560, PMCID: PMC8642278, DOI: 10.1158/1541-7786.mcr-21-0456.Peer-Reviewed Original ResearchConceptshistone deacetylase inhibitor vorinostatpatient-derived tumor xenograftshomology-directed repairisocitrate dehydrogenase 1/2 mutationshistone deacetylase inhibitionIDH1 mutant cellsgreater cell deathHDACi treatmentinhibitor vorinostattumor xenograftsdeacetylase inhibitionIDH1/2 mutationspotential biomarkersspecific cancersmutant cancerscancercancer cellsDNA repair defectsmalignancyvorinostatDNA double-strand breaksgliomashistone hypermethylationcell deathPARPiDirect targeting of amplified gene loci for proapoptotic anticancer therapy
Kaushik Tiwari M, Colon-Rios DA, Tumu HCR, Liu Y, Quijano E, Krysztofiak A, Chan C, Song E, Braddock DT, Suh HW, Saltzman WM, Rogers FA. Direct targeting of amplified gene loci for proapoptotic anticancer therapy. Nature Biotechnology 2021, 40: 325-334. PMID: 34711990, PMCID: PMC8930417, DOI: 10.1038/s41587-021-01057-5.Peer-Reviewed Original ResearchConceptsDNA double-strand breakstriplex-forming oligonucleotidesDNA damage responsedouble-strand breaksdrug resistancegene amplificationp53-independent apoptosisHER2-positive breastovarian cancer modelhuman tumor xenograftsinduction of apoptosisgenomic locinumber of drugscellular functionsdamage responsegene locusprotein productsHER2-positive cancer cellsdriver genesclinical efficacycombat drug resistanceDNA damageHER2 amplificationtherapeutic strategiestumor xenografts